Search results
Showing 16 to 30 of 38 results for bisphosphonates
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
every day can help reduce your chance of getting bowel cancer. Bisphosphonates for treating osteoporosis Everyone's bones get weaker as...
Question [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the inhibitory effects on bone...
Recommendation ID NG35/5 Question Bisphosphonates for the prevention of bone disease:- What is the effectiveness of monthly zoledronic
Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184)
This guideline covers investigating and managing gastro-oesophageal reflux disease (GORD) and dyspepsia in people aged 18 and over. It aims to improve the treatment of GORD and dyspepsia by making detailed recommendations on Helicobacter pylori eradication, and specifying when to consider laparoscopic fundoplication and referral to specialist services.
Osteoporosis: bone sparing agents (75 years and over) (IND92)
This indicator covers the percentage of patients aged 75 or over with a fragility fracture on or after 1 April 2012, who are currently treated with an appropriate bone-sparing agent. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM31
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
Evidence-based recommendations on radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases. This involves inserting a needle-like probe containing an electrode into the spinal metastases. This produces an electrical current that aims to relieve pain and other symptoms.
View recommendations for IPG759Show all sections
Discontinued [GID-TA10072]
This indicator covers the percentage of patients aged 50 or over and who have not attained the age of 75, with a record of a fragility fracture on or after 1 April 2012, in whom osteoporosis is confirmed on DXA scan, who are currently treated with an appropriate bone-sparing agent. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM30
Radiofrequency ablation for palliation of painful spinal metastases (IPG758)
Evidence-based recommendations on radiofrequency ablation for palliation of painful spinal metastases. This involves inserting a needle-like probe containing an electrode into the spinal metastases. This produces an electrical current that aims to relieve pain and other symptoms.
View recommendations for IPG758Show all sections
What are the optimal management strategies for primary hyperparathyroidism during pregnancy?
cinacalcet should not be offered during pregnancy. They also agreed that bisphosphonates are potentially harmful for the mother and the...
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.
The review found several randomised controlled trials of stopping bisphosphonates (although not clearly in populations with...
Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)
This evidence summary has been updated and replaced by NICE guideline NG101.